Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline's Advair is positioned ahead of Boehringer Ingelheim/Pfizer's Spiriva in first and second lines of therapy for chronic obstructive pulmonary disease (COPD). Advair captures 55.3 percent of its total patients from first- and second-lines of therapy whereas Spiriva captures 51.4 percent. Advair also has higher patient shares in first- and second-line therapy in newly diagnosed patients.

"Although Advair is currently positioned just ahead of Spiriva in lines of therapy, over the next two years, we expect Spiriva use to grow more rapidly than Advair's use, and Spiriva may inch ahead of Advair in lines of therapy," stated Michael Malecki, Ph.D., analyst at Decision Resources. "In order to get ahead of Advair, Spiriva will need to see growing use among primary care physicians because a lot of Advair's use is driven by these physicians."

The new report entitled Treatment Algorithms in Chronic Obstructive Pulmonary Disease also finds that AstraZeneca's Symbicort-a combination inhaler in the same class as Advair-will be used more frequently in second-line therapy over the next two years. Symbicort is not yet FDA approved for COPD (the drug is preregistered for this indication), but it is approved for asthma.

"The net number of surveyed physicians who expect to increase their use of long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations such as Symbicort and Advair, in the second line is greater than those who have this expectation for the first line," added Dr. Malecki. "Because Advair already captures a larger share of the first line than any other single agent, and because more surveyed physicians indicate they will increase their second line use of Symbicort, we think growth of LABA/ICS inhalers in the first and second lines over the next two years will be driven primarily by uptake of Symbicort in these lines of therapy."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Natalia Morales              Elizabeth Marshall   Decision Resources           Decision Resources, Inc.   781-296-2691                 781-296-2563 

SOURCE: Decision Resources

CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,; or Elizabeth Marshall of Decision Resources, Inc.,

Radiopharmaceutical Cardiolite has 15 Percent More Market Share than Myoview for September 2008

View Now